

PRODUCT MONOGRAPH

TAZOCIN

sterile piperacillin sodium/tazobactam sodium

Lyophilized Powder for Injection

For Intravenous Use

Piperacillin 2gm (as piperacillin sodium) and Tazobactam 0.25 g (as tazobactam sodium) per vial
Piperacillin 3gm (as piperacillin sodium) and Tazobactam 0.375 g (as tazobactam sodium) per vial
Piperacillin 4gm (as piperacillin sodium) and Tazobactam 0.5 g (as tazobactam sodium) per vial

Therapeutic Classification

Antibiotic/ β -lactamase Inhibitor

©
WYETH CANADA
MONTREAL, CANADA

Control No. 122728

Date of Revision:
August 20, 2008

THIS PRODUCT MONOGRAPH IS THE EXCLUSIVE PROPERTY OF WYETH CANADA AND CAN NOT BE REFERENCED, PUBLISHED OR COPIED WITHOUT THE WRITTEN APPROVAL OF WYETH CANADA.

PRODUCT MONOGRAPH**TAZOCIN**

sterile piperacillin sodium/tazobactam sodium

Lyophilized Powder for Injection

For Intravenous Use

THERAPEUTIC CLASSIFICATION

Antibiotic/ β -lactamase Inhibitor

ACTION AND CLINICAL PHARMACOLOGY

TAZOCIN (sterile piperacillin sodium/tazobactam sodium) is an injectable antibacterial combination consisting of the semisynthetic antibiotic piperacillin sodium and the β -lactamase inhibitor tazobactam sodium for intravenous administration.

Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis. *In vitro*, piperacillin is active against a variety of gram-positive and gram-negative aerobic and anaerobic bacteria. Tazobactam sodium is a β -lactamase inhibitor. Tazobactam, in combination with piperacillin enhances and extends the antibiotic spectrum of piperacillin to include β -lactamase producing bacteria normally resistant to piperacillin.

Piperacillin is metabolized to a minor microbiologically active desethyl metabolite. Tazobactam

is metabolized to a single metabolite which lacks pharmacological and antibacterial activities. Both tazobactam and piperacillin are eliminated by the kidney via glomerular filtration and tubular secretion. Tazobactam and its metabolite are eliminated primarily by renal excretion with 80% of the dose as unchanged drug and the remainder as the single metabolite. Piperacillin is excreted rapidly as unchanged drug, with 68% of the dose in the urine. Piperacillin, tazobactam and desethyl piperacillin are also secreted into the bile.

Tazobactam and piperacillin are widely distributed into tissues and body fluids including, but not limited to, intestinal mucosa, gallbladder, lung, female reproductive tissues (uterus, ovary and fallopian tube) interstitial fluid and bile. Mean tissue concentrations were generally 50-100% of those in plasma. Distribution of tazobactam and piperacillin into cerebrospinal fluid is low in subjects with non-inflamed meninges, as with other penicillins.

In subjects with renal impairment, the half-lives of tazobactam and piperacillin, after single doses, increase with decreasing creatinine clearance. At creatinine clearance below 20 mL/min., the increase in half-life is four-fold for tazobactam and two-fold for piperacillin compared to subjects with normal renal function. Dosage adjustments for TAZOCIN are recommended when creatinine clearance is below 40 mL/min in patients receiving the recommended daily dose of TAZOCIN. (see DOSAGE AND ADMINISTRATION).

Hemodialysis removes 30-40% of a TAZOCIN dose with an additional 5% of the tazobactam dose removed as the tazobactam metabolite. Peritoneal dialysis removes approximately 21% and

6% of the tazobactam and piperacillin doses, respectively, with up to 16% of the tazobactam dose removed as the tazobactam metabolite. For dosage recommendations for patients undergoing hemodialysis, see DOSAGE AND ADMINISTRATION.

Tazobactam and piperacillin half-lives increase by approximately 18 % and 25% respectively, in patients with hepatic cirrhosis compared to healthy subjects. However, dosage adjustment of TAZOCIN due to hepatic cirrhosis is not necessary.

INDICATIONS AND USAGE

TAZOCIN (sterile piperacillin sodium/tazobactam sodium) is indicated for the treatment of patients with systemic and/or local bacterial infections, caused by piperacillin resistant, piperacillin/tazobactam susceptible, β -lactamase producing strains of the designated microorganisms in the specified conditions listed below:

a) **INTRA-ABDOMINAL INFECTIONS**

Appendicitis (complicated by rupture or abscess) and peritonitis caused by piperacillin resistant, β -lactamase producing strains of *Escherichia coli* or members of the *Bacteroides fragilis* group.

b) **SKIN AND SKIN STRUCTURE INFECTIONS**

Uncomplicated and complicated skin and skin structure infections, including cellulitis,

cutaneous abscess, acute ischemic/diabetic foot infections caused by piperacillin resistant β -lactamase producing strains of *Staphylococcus aureus* (not methicillin-resistant strains).

c) **GYNECOLOGICAL INFECTIONS**

Postpartum endometritis or pelvic inflammatory disease caused by piperacillin resistant, β -lactamase producing strains of *Escherichia coli*.

d) **COMMUNITY-ACQUIRED LOWER RESPIRATORY TRACT INFECTIONS**

Community-acquired pneumonia (moderate severity only) caused by piperacillin resistant, β -lactamase producing strains of *Haemophilus influenzae*.

e) **NOSOCOMIAL PNEUMONIA**

Nosocomial pneumonia (moderate to severe) caused by piperacillin-resistant, β -lactamase producing strains of *Staphylococcus aureus* and by piperacillin/tazobactam-susceptible *Acinetobacter baumannii*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* (Nosocomial pneumonia caused by *P. aeruginosa* should be treated in combination with an aminoglycoside). (See **DOSAGE AND ADMINISTRATION**).

While TAZOCIN is indicated only for the conditions listed above, infections caused by piperacillin susceptible organisms are also amenable to TAZOCIN treatment due to its

piperacillin content. The tazobactam component of this combination product does not decrease the activity of the piperacillin component against piperacillin susceptible organisms. Therefore, the treatment of polymicrobial infections caused by piperacillin susceptible organisms and β -lactamase producing organisms susceptible to TAZOCIN should not require the addition of another antibiotic.

TAZOCIN may be useful as presumptive therapy in the indicated conditions prior to identification of causative organisms because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic organisms.

Appropriate cultures should usually be performed before initiating antimicrobial treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to TAZOCIN. Antimicrobial therapy should be adjusted, if appropriate, once results of culture(s) and antimicrobial susceptibility testing are known.

CONTRAINDICATIONS

The use of TAZOCIN (sterile piperacillin sodium/tazobactam sodium) is contraindicated in patients with a history of allergic reactions to any of the penicillins and/or cephalosporins or β -lactamase inhibitors.

WARNINGS

SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC /ANAPHYLACTOID [INCLUDING SHOCK]) REACTIONS HAVE BEEN REPORTED IN INDIVIDUALS RECEIVING THERAPY WITH PENICILLINS. THESE REACTIONS ARE MORE APT TO OCCUR IN INDIVIDUALS WITH A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE HYPERSENSITIVITY REACTIONS WHEN TREATED WITH CEPHALOSPORINS.

BEFORE INITIATING THERAPY WITH TAZOCIN (PIPERACILLIN SODIUM /TAZOBACTAM SODIUM), CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS DURING THERAPY WITH TAZOCIN, THE ANTIBIOTIC SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED. SERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE, OXYGEN AND INTRAVENOUS STEROIDS AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.

Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents, including TAZOCIN. CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of

colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agent. CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth of *Clostridium difficile*. *Clostridium difficile* produces toxins A and B, which contribute to the development of CDAD. CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy.

If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against *Clostridium difficile*. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against *Clostridium difficile*. Surgical evaluation should be instituted as clinically indicated, as surgical intervention may be required in certain severe cases (see ADVERSE REACTIONS section).”

PRECAUTIONS

General

Bleeding manifestations or significant leukopenia following prolonged administration have occurred in some patients receiving β -lactam antibiotics, including piperacillin. These reactions have sometimes been associated with abnormalities of coagulation tests such as clotting time, platelet aggregation and prothrombin time and are more likely to occur in patients with renal

failure. If bleeding manifestations occur, the antibiotic should be discontinued and appropriate therapy instituted.

The possibility of the emergence of resistant organisms that might cause superinfections should be kept in mind. If this occurs, appropriate measures should be taken.

As with other penicillins, patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given intravenously (particularly in the presence of renal failure).

TAZOCIN contains a total of 2.79 mEq (64 mg) of sodium (Na^+) per gram of piperacillin in the combination product. This should be considered when treating patients requiring restricted salt intake. Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics.

Leukopenia and neutropenia may occur, especially during prolonged therapy. Therefore, periodic assessment of hematopoietic function should be performed.

As with other semisynthetic penicillins, piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.

In patients with creatinine clearance <40 mL/min and dialysis patients [hemodialysis and chronic ambulatory peritoneal dialysis (CAPD)], the intravenous dose should be adjusted to the degree of

renal function impairment (see DOSAGE AND ADMINISTRATION).

Because of chemical instability, TAZOCIN should not be used for intravenous administration with solutions containing only sodium bicarbonate (see incompatibilities section).

TAZOCIN should not be added to blood products or albumin hydrolysates.

Pediatric use

Safety and efficacy in children below the age of 12 have not been established.

Obstetrics and Teratology

Reproduction studies have been performed in rats and have revealed no evidence of impaired fertility due to piperacillin/tazobactam administered up to a dose which is similar to the maximum recommended human daily dose based on body-surface area (mg/m^2). Teratology studies have been performed in mice and rats and have revealed no evidence of harm to the fetus due to piperacillin/tazobactam at doses 1-2 and 2-3 times the human dose of piperacillin and tazobactam, respectively, based on body-surface area (mg/m^2).

Piperacillin: Reproduction and teratology studies have been performed in mice and rats and have revealed no evidence of impaired fertility or harm to the fetus due to piperacillin administered up to a dose which is half (mice) or similar (rats) to the human dose based on body-surface area (mg/m^2).

Tazobactam: Reproduction studies have been performed in rats and have revealed no evidence of impaired fertility due to tazobactam administered up to a dose 3 times the human dose based on body-surface area (mg/m^2). Teratology studies have been performed in mice and rats and have revealed no evidence of harm to the fetus due to tazobactam up to a dose which is 6 (mice) and 14 (rats) times the human dose based on body-surface area (mg/m^2). In rats, tazobactam crosses the placenta. Concentrations in the fetus are less than or equal to 10% of that found in maternal plasma.

There are no adequate and well-controlled studies with the piperacillin/tazobactam combination or with piperacillin or tazobactam alone in pregnant women. Piperacillin and tazobactam cross the placenta. Because animal reproduction studies are not always predictive of human response pregnant women should be treated with TAZOCIN only if the expected benefit outweighs the possible risks to the pregnant woman and fetus.

Nursing Mothers

Caution should be exercised when TAZOCIN is administered to nursing mothers. Piperacillin is excreted in low concentrations in human milk; tazobactam concentrations in milk have not been studied. Women who are breast-feeding should be treated only if the expected benefit outweighs the possible risks to the woman and child.

Elderly

Patients over 65 years of age are not at an increased risk of developing adverse effects solely because of age. However, dosage should be adjusted in the presence of renal insufficiency (see DOSAGE AND ADMINISTRATION).

In general, dose selection for an elderly patient should be approached with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Tazocin contains 64 mg (2.79 mEq) of sodium per gram of piperacillin in the combination product. At the usual recommended doses, patients would receive between 768 and 1024 mg/day (33.5 and 44.6 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to diseases such as congestive heart failure.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are more likely to have decreased renal function and therefore care should be taken in dose selection. It may be useful to monitor renal function.

Drug Interactions

Aminoglycosides

The mixing of beta-lactam antibiotics with aminoglycosides *in vitro* can result in substantial inactivation of the aminoglycoside. However, amikacin and gentamicin were determined to be compatible *in vitro* with reformulated TAZOCIN containing EDTA in certain diluents at specific concentrations for a simultaneous Y-site infusion (see DOSAGE AND ADMINISTRATION).⁴²

The inactivation of aminoglycosides in the presence of penicillin-class drugs has been recognized. It has been postulated that penicillin-aminoglycoside complexes form; these complexes are microbiologically inactive and of unknown toxicity. Sequential administration of Tazocin with tobramycin to patients with normal renal function and mild to moderate renal impairment has been shown to modestly decrease serum concentrations of tobramycin but does not significantly affect tobramycin pharmacokinetics. When aminoglycosides are administered in combination with piperacillin to patients with end-stage renal disease requiring hemodialysis, the concentrations of the aminoglycosides (especially tobramycin) may be significantly altered and should be monitored. Since aminoglycosides are not equally susceptible to inactivation by piperacillin, consideration should be given to the choice of the aminoglycoside when administered in combination with piperacillin to these patients.

Probenecid

Concomitant administration of TAZOCIN and probenecid results in prolonged half-life of piperacillin (21%), and tazobactam (71%) and lower renal clearance for both piperacillin and

tazobactam; however, peak plasma concentrations of either drug are unaffected.

Vancomycin

No pharmacokinetic interactions are found between TAZOCIN and vancomycin.

Heparin

Coagulation parameters should be tested more frequently and monitored regularly, during simultaneous administration of high doses of heparin, oral anticoagulants and other drugs that may affect the blood coagulation system and/or the thrombocyte function.

Vecuronium

Piperacillin used concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockade of vecuronium. TAZOCIN (piperacillin/tazobactam) could produce the same phenomenon if given along with vecuronium. Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin. (see package insert for vecuronium bromide).

Methotrexate

Piperacillin may reduce the excretion of methotrexate; therefore, serum levels of methotrexate should be monitored in patients to avoid drug toxicity.

Where TAZOCIN is administered concurrently with another antibiotic the drugs should not be mixed in the same solution but must be administered separately.

Drug/Laboratory Test Interactions

As with other penicillins, the administration of TAZOCIN may result in a false-positive reaction for glucose in the urine using a copper-reduction method (CLINITEST^{®*}). It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as DIASTIX^{®*} or TES-TAPE^{®**}) be used.

There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of Aspergillus infection. Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported. Therefore, positive test results in patients receiving piperacillin/tazobactam should be interpreted cautiously and confirmed by other diagnostic methods.

*CLINITEST[®] and DIASTIX[®] are registered trademarks of Ames Division, Miles Laboratories, Inc.

** TES-TAPE[®] is a registered trademark of Eli Lilly and Company.

ADVERSE REACTIONS

Adverse Events from Clinical Trials

During the clinical investigations, 2621 patients worldwide were treated with TAZOCIN in phase 3 trials. In the key North American clinical trials (n=830 patients), 90% of the adverse events reported were mild to moderate in severity and transient in nature. However, in 3.2% of the patients treated worldwide, TAZOCIN was discontinued because of adverse events primarily involving the skin (1.3%), including rash and pruritus; the gastrointestinal system (0.9%), including diarrhea, nausea, and vomiting; and allergic reactions (0.5%).

Adverse local reactions that were reported, irrespective of relationship to therapy with TAZOCIN, were phlebitis (1.3%), injection site reaction (0.5%), pain (0.2%), inflammation (0.2%), thrombophlebitis (0.2%), and edema (0.1%).

Based on patients from the North American trials (n=1063), the events with the highest incidence in patients, irrespective of relationship to TAZOCIN therapy, were diarrhea (11.3%); headache (7.7%); constipation (7.7%); nausea (6.9%); insomnia (6.6%); rash (4.2%), including maculopapular, bullous, urticarial, and eczematoid; vomiting (3.3%); dyspepsia (3.3%); pruritus (3.1 %); stool changes (2.4%); fever (2.4%); agitation (2.1 %); pain (1.7%); moniliasis (1.6%); hypertension (1.6%); dizziness (1.4%); abdominal pain (1.3%); chest pain (1.3%); edema (1.2%); anxiety (1.2%); rhinitis (1.2%); and dyspnea (1.1%).

Additional adverse systemic clinical events reported in 1.0% or less of the patients are listed below within each body system:

Autonomic nervous system: hypotension, ileus, syncope

Body as a whole: rigors, back pain, malaise, candidal superinfection

Cardiovascular: tachycardia, including supraventricular and ventricular; bradycardia; arrhythmia, including atrial fibrillation, ventricular fibrillation, cardiac arrest, cardiac failure, circulatory failure, myocardial infarction

Central nervous system: tremor, convulsions, vertigo

Gastrointestinal: melena, flatulence, hemorrhage, gastritis, hiccough, ulcerative stomatitis, jaundice

Pseudomembranous colitis was reported in one patient during the clinical trials. The onset of pseudomembranous colitis symptoms may occur during or over 2 months after the administration of antibacterial treatment. (See WARNINGS.)

Hearing: tinnitus

Hypersensitivity: anaphylaxis (including shock). Incidence of rash and fever is higher in patients with cystic fibrosis

Metabolic and Nutritional: symptomatic hypoglycemia, thirst

Musculo-skeletal: myalgia, arthralgia

Platelet, Bleeding, Clotting: mesenteric embolism, purpura, epistaxis, pulmonary embolism (See PRECAUTIONS - General.)

Psychiatric: confusion, hallucination, depression

Reproductive, Female: leukorrhea, vaginitis

Respiratory: pharyngitis, pulmonary edema, bronchospasm, coughing

Skin and Appendages: genital pruritus, diaphoresis, toxic epidermal necrolysis

Special senses: taste perversion

Urinary: retention, dysuria, oliguria, hematuria, incontinence

Vision: photophobia

Vascular (extracardiac): flushing

Nosocomial Pneumonia Trials

In a completed study of nosocomial pneumonia, 222 patients were treated with TAZOCIN in a dosing regimen of 4.5 g every 6 hours in combination with an aminoglycoside and 215 patients were treated with a comparator in combination with an aminoglycoside. In this trial, treatment-emergent adverse events were reported by 402 patients, 204 (91.9%) in the piperacillin/tazobactam group and 198 (92.1%) in the comparator group. Twenty-five (25, 11.0%) patients in the piperacillin/tazobactam group and 14 (6.5%) in the comparator group ($p > 0.05$) discontinued treatment due to an adverse event.

In this study of TAZOCIN in combination with an aminoglycoside, adverse events that occurred in more than 1% of patients and were considered by the investigator to be drug-related were: diarrhea (17.6%), fever (2.7%), vomiting (2.7%), urinary tract infection (2.7%), rash (2.3%), abdominal pain (1.8%), generalized edema (1.8%), moniliasis (1.8%), nausea (1.8%), oral moniliasis (1.8%), BUN increased (1.8%), creatinine increased (1.8%), peripheral edema (1.8%), abdomen enlarged (1.4%), headache (1.4%), constipation (1.4%), liver function tests abnormal (1.4%), thrombocytopenia (1.4%), excoriations¹ (1.4%), and sweating (1.4%).

Drug-related adverse events reported in 1% or less of patients in the nosocomial pneumonia study

¹ These were coded under the COSTART term skin necrosis in CSR-44881, Supportive Table 10-3.

of TAZOCIN with an aminoglycoside were: acidosis, acute kidney failure, agitation, alkaline phosphatase increased, anemia, asthenia, atrial fibrillation, chest pain, CNS depression, colitis, confusion, convulsion, cough increased, thrombocytopenia, dehydration, depression, diplopia, drug level decreased, dry mouth, dyspepsia, dysphagia, dyspnea, dysuria, eosinophilia, fungal dermatitis, gastritis, glossitis, grand mal convulsion, hematuria, hyperglycemia, hypernatremia, hypertension, hypertonia, hyperventilation, hypochromic anemia, hypoglycemia, hypokalemia, hyponatremia, hypophosphatemia, hypoxia, ileus, injection site edema, injection site pain, injection site reaction, kidney function abnormal, leukocytosis, leukopenia, local reaction to procedure, melena, pain, prothrombin decreased, pruritus, respiratory disorder, AST (SGOT) increased, ALT (SGPT) increased, sinus bradycardia, somnolence, stomatitis, stupor, tremor, tachycardia, ventricular extrasystoles, and ventricular tachycardia.

Post-Marketing Experience

Additional adverse events reported from worldwide marketing experience with TAZOCIN occurring under circumstances where causal relationship to TAZOCIN is uncertain:

Gastrointestinal: hepatitis, cholestatic jaundice

Hematologic: hemolytic anemia, anemia, thrombocytosis, agranulocytosis, pancytopenia

Immune: hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock)

Infections: candidial superinfections

Renal: interstitial nephritis, renal failure

Skin and Appendages: erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis

Adverse Laboratory Events

Changes in laboratory parameters, without regard to drug relationship, were reported in all studies, including studies of nosocomial pneumonia in which a higher dose of TAZOCIN (piperacillin and tazobactam for injection) was used in combination with an aminoglycoside. The changes in laboratory parameters include:

Hematologic: Agranulocytosis, pancytopenia, anemia, decreases in hemoglobin and hematocrit, thrombocytopenia, increases in platelet count, eosinophilia, leukopenia, neutropenia. The leukopenia/neutropenia associated with TAZOCIN administration appears to be reversible and most frequently associated with prolonged administration, i.e., ≥ 21 days of therapy. These patients were withdrawn from therapy; some had accompanying systemic symptoms (e.g., fever, rigors, chills).

Coagulation: Positive direct Coombs test, prolonged prothrombin time, prolonged partial thromboplastin time, bleeding time prolonged

Hepatic: Transient elevations of AST (SGOT), ALT (SGPT), alkaline phosphatase, bilirubin, gamma-glutamyltransferase increased

Renal: Increases in serum creatinine, blood urea nitrogen, renal failure

Urinalysis: Proteinuria, hematuria, pyuria

Additional laboratory events include abnormalities in electrolytes (i.e., increases and decreases in sodium, potassium, and calcium), hyperglycemia, decreases in total protein or albumin. In individuals with liver disease or those receiving cytotoxic therapy or diuretics, TAZOCIN has been reported rarely to produce a decrease in serum potassium levels at high doses of piperacillin.

The following adverse reactions have also been reported for PIPRACIL® (sterile piperacillin sodium):

Skin and appendages: Erythema multiforme and Stevens-Johnson syndrome, rarely reported

Gastrointestinal: Cholestatic hepatitis

Renal: Rarely, interstitial nephritis

Skeletal: Prolonged muscle relaxation (See PRECAUTIONS - Drug interactions.)

SYMPTOMS AND TREATMENT OF OVERDOSAGE

There have been post-marketing reports of overdose with TAZOCIN. The majority of those events experienced including nausea, vomiting, and diarrhea have also been reported with the usual recommended dosages. Patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given intravenously (particularly in the presence of renal failure).

Treatment should be supportive and symptomatic according to the patient's clinical presentation.

Excessive serum levels of either tazobactam or piperacillin may be reduced by hemodialysis, although no specific antidote is known. As with other penicillins, neuromuscular excitability or convulsions have occurred following large intravenous doses, primarily in patients with impaired renal function.

In the case of motor excitability or convulsions, general supportive measures, including administration of anticonvulsive agents (eg. diazepam or barbiturates) may be considered.

For the management of suspected drug overdose, contact your regional Poison Control Center.

DOSAGE AND ADMINISTRATION

Dosage

The usual total daily dose of TAZOCIN (sterile piperacillin sodium/tazobactam sodium) for adults is 12 g/1.5 g, given as 3 g/0.375 g every six hours.

Clinical trial data in the treatment of intra-abdominal infections support the efficacy of 4 g/0.5 g given every eight hours.

Initial presumptive treatment of patients with nosocomial pneumonia should start with TAZOCIN at a dosage of 4.5 g every six hours plus an aminoglycoside, totalling 18.0 g (16.0 g piperacillin sodium/2.0 g tazobactam sodium). Treatment with the aminoglycoside should be continued in patients from whom *Pseudomonas aeruginosa* is isolated. If *Pseudomonas aeruginosa* is not isolated, the aminoglycoside may be discontinued at the discretion of the treating physician.

Due to the *in vitro* inactivation of the aminoglycoside by beta-lactam antibiotics, TAZOCIN[®] and the aminoglycoside should be reconstituted and diluted separately when concomitant therapy with aminoglycosides is indicated (See Drug Interactions).

When concomitant therapy with an aminoglycoside is indicated, TAZOCIN and the aminoglycoside should be administered separately.

In certain circumstances where co-administration is preferred, compatibility for simultaneous co-administration via Y-site infusion has been established for the TAZOCIN formulation containing EDTA supplied in vials with the following aminoglycosides under the following conditions:⁴²

The following compatibility information only applies to the reformulated TAZOCIN containing EDTA, and does not apply to other formulations of piperacillin/tazobactam including the previous TAZOCIN (piperacillin/tazobactam) brand formulation:

Aminoglycoside	Piperacillin/ tazobactam (grams) dose	Piperacillin/ tazobactam Diluent Volume (mL)	Aminoglycoside Concentration Range[‡] (mg/mL)	Acceptable Diluents
Amikacin	2.25,3.375,4.5	50,100,150	1.75 – 7.5	0.9% sodium chloride or 5% dextrose
Gentamicin	2.25,3.375,4.5	100,150	0.7 – 3.32	0.9% sodium chloride

[‡]The dose of aminoglycoside should be based on patient weight, status of infection (serious or life threatening) and renal function (creatinine clearance).

Tazocin is not compatible with tobramycin for simultaneous coadministration via Y-site infusion. Compatibility of TAZOCIN with other aminoglycosides has not been established. Only the concentration and diluents of amikacin or gentamicin with the dosages of TAZOCIN listed in the above table have been established as compatible for co-administration via Y-site infusion. Simultaneous administration via Y-site infusion in any

manner other than listed above may result in inactivation of the aminoglycoside by TAZOCIN.

Renal Insufficiency

In patients with renal insufficiency, the intravenous dose should be adjusted to the degree of actual renal function impairment. In patients with nosocomial pneumonia receiving concomitant aminoglycoside therapy, the aminoglycoside dosage should be adjusted according to the recommendations of the aminoglycoside used. The recommended daily doses of Tazocin for patients with renal insufficiency are as follows:

Recommended Dosing of TAZOCIN in Patients with Normal Renal Function and Renal Insufficiency (As total grams piperacillin/tazobactam)

Renal Function (Creatinine Clearance, mL/min)	All Indications (except Nosocomial Pneumonia)	Nosocomial Pneumonia
>40 mL/min	3.375 q6h	4.5 q6h
20-40 mL/min*	2.25 q6h	3.375 q6h
<20 mL/min*	2.25 q8h	2.25 q6h
Hemodialysis**	2.25 q12h	2.25 q8h
CAPD	2.25 q 12h	2.25 q8h

* Creatinine clearance for patients not receiving hemodialysis

** 0.75g should be administered following each hemodialysis session on hemodialysis days

For patients on hemodialysis, the maximum dose is 2.25 g piperacillin/tazobactam given every twelve hours for all indications other than nosocomial pneumonia and 2.25 g every eight hours for nosocomial pneumonia. In addition, because hemodialysis removes 30% to 40% of TAZOCIN

dose in four hours, one additional dose of 0.75 g piperacillin/tazobactam should be administered following each dialysis period. For patients with renal failure, measurement of serum levels of TAZOCIN will provide additional guidance for adjusting dosage.

Dosage adjustment is based on pharmacokinetic data. Clinical studies with TAZOCIN have not been performed in patients with impaired renal function.

Duration of Therapy

The usual duration of TAZOCIN treatment is from seven to ten days. However, the recommended duration of TAZOCIN treatment of nosocomial pneumonia is 7 to 14 days. In all conditions, the duration should be guided by the severity of the infection and the patient's clinical and bacteriological progress.

Administration

TAZOCIN should be administered by intravenous infusion over 30 minutes.


(See PHARMACOLOGY).

PHARMACEUTICAL INFORMATION**Drug Substance**

Proper Name: Tazobactam Sodium.

Chemical Name: Sodium (2*S*, 3*S*, 5*R*)-3-methyl-7-oxo-3-(1*H*-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide

Structural Formula: tazobactam sodium



Chemical Formula: $C_{10}H_{11}N_4NaO_5S$

Molecular Weight: 322.29


Description : Tazobactam is a white to pale-yellow crystalline powder. Its solubility in water is 5.5mg/mL with a resulting pH of 1.9, and the aqueous solubility

of sodium salt is at least 500mg/mL. There is no melting point; the material decomposes at above 176°C.

Proper Name: Piperacillin Sodium

Chemical Name: Sodium (2*S*,5*R*,6*R*)-6-[(*R*)-2-(4-ethyl-2,3-dioxo-1-piperazine-carboxyamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylate.

Structural Formula: piperacillin sodium



Chemical Formula: $C_{23}H_{26}N_5NaO_7S$

Molecular Weight: 539.5

Description: Piperacillin monohydrate is a white to off-white crystalline powder. The aqueous solubility of its sodium salt is 1g/1.4mL and the pH of 25% w/v solution is 5.5-7.0. The melting point of the piperacillin sodium is 183°-185°C with decomposition.

Composition

Sterile piperacillin sodium/tazobactam sodium parenteral combination, is a white to off-white sterile, cryodesiccated powder or cake consisting of tazobactam and piperacillin as their sodium salts packaged in glass vials.

Each TAZOCIN 2.25 gram vial provides tazobactam sodium equivalent to 0.25 gram of tazobactam and piperacillin sodium equivalent to 2 grams of piperacillin. The product also contains 0.5 mg of edetate disodium (dihydrate), 69 mg of citric acid (monohydrate) and 5.58 mEq (128 mg) of total sodium per vial.

Each TAZOCIN 3.375 gram vial provides tazobactam sodium equivalent to 0.375 gram of tazobactam and piperacillin sodium equivalent to 3 grams of piperacillin. The product also contains 0.75 mg of edetate disodium (dihydrate), 104 mg of citric acid (monohydrate) and 8.38 mEq (192 mg) of total sodium per vial.

Each TAZOCIN 4.5 gram vial provides tazobactam sodium equivalent to 0.5 gram of tazobactam and piperacillin sodium equivalent to 4 grams of piperacillin. The product also contains 1 mg of

edetate disodium (dihydrate), 139 mg of citric acid (monohydrate) and 11.17 mEq (256 mg) of total sodium per vial.

Stability and Storage Recommendations

TAZOCIN vials should be stored at controlled room temperature 15-30°C (59-86°F).

Single Dose Vials. Discard unused portions.

Reconstituted Solutions

Reconstitute TAZOCIN with at least 5 mL of a suitable diluent per gram of piperacillin from the list of diluents provided below. Swirl until dissolved. It should be further diluted to the desired final volume with an acceptable diluent.

Reconstitution

Vial Size (piperacillin/ tazobactam)	Volume of diluent to be added to vial	Approximate available volume	Nominal concentration per mL
2.25g (2g/0.25g)	10 mL	11.60 mL	0.194 g/mL (0.172g/mL/0.022g/mL)
3.375g (3g/0.375g)	15 mL	17.36 mL	0.194 g/mL (0.172g/mL/0.022g/mL)
4.50g (4g/0.50g)	20 mL	23.15 mL	0.194 g/mL (0.172g/mL/0.022g/mL)

<p>Reconstitute Tazocin per gram of piperacillin with 5 mL of a <i>Compatible Reconstitution Diluent</i> (listed below)</p>	<p>Further dilute the reconstituted TAZOCIN with 50 mL to 150 mL of a <i>Compatible Intravenous Solution</i> (listed below)</p>
<p>0.9% Sodium Chloride Injection Sterile Water for Injection 5% Dextrose Injection</p>	<p>0.9% Sodium Chloride Injection Sterile Water for Injection* 5% Dextrose Injection Lactated Ringer's Injection (Only compatible with reformulated TAZOCIN containing EDTA)**</p> <p>*Maximum recommended volume per dose of Sterile Water for Injection is 50 mL. **Compatibility was studied in 250 mL IV bags only.</p>
<p>Bacteriostatic Sodium Chloride Injection (with benzyl alcohol) Bacteriostatic Water for Injection (with benzyl alcohol) Bacteriostatic Water for Injection (with parabens)</p>	<p>0.9% Sodium Chloride Injection</p>

Lactated Ringer's Injection is only compatible with the reformulated TAZOCIN containing EDTA⁴³

Intermittent Intravenous Infusion - Reconstitute as previously described, with 5 mL of an acceptable diluent per 1 gram of piperacillin and then further dilute in the desired volume (at least 50 mL). This diluted solution must be used immediately. Administer by infusion over a period of at least 30 minutes. During the infusion it is desirable to discontinue the primary infusion solution.

Stability of TAZOCIN Following Reconstitution

TAZOCIN is stable in glass and plastic containers (plastic syringes, I.V. bags and tubing) when reconstituted with acceptable diluents.

Stability studies of Tazocin in glass vials have demonstrated chemical stability [potency, pH of reconstituted solution, appearance and description, and clarity of solution] for up to 24 hours at room temperature and up to 48 hours at refrigerated temperatures. Discard unused portions after storage for 24 hours at room temperature or 48 hours when refrigerated.⁴³

DUE TO MICROBIAL CONSIDERATIONS, INTRAVENOUS ADMIXTURES ARE USUALLY RECOMMENDED FOR USE WITHIN A MAXIMUM OF 24 HOURS AT ROOM TEMPERATURE OR 72 HOURS WHEN REFRIGERATED (2-8 °C).

Stability studies of TAZOCIN in polyolefin I.V. bags have demonstrated chemical stability (potency, appearance and description and clarity of solution) for up to 24 hours at room temperature and up to 72 hours at refrigerated temperature. Stability and compatibility of Tazocin in PVC I.V. bags have not been established. TAZOCIN contains no preservatives. Appropriate consideration of aseptic technique should be used.^{43, 44}

As with all parenteral drug products, intravenous admixtures should be inspected visually for clarity, particulate matter, precipitate, discoloration and leakage prior to administration, whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate, discoloration or leakage should not be used. Discard unused portion.

Incompatibilities

Not to be added to blood products or albumin hydrolysates.

Because of chemical instability, TAZOCIN should not be used for intravenous administration with solutions containing sodium bicarbonate alone. It may be used with intravenous admixtures containing other ingredients as well as sodium bicarbonate for up to 24 hours at room temperature and 48 hours refrigerated.

Solutions containing TAZOCIN and protein hydrolysates or amino acids should be used within 12 hours if stored at room temperature and 24 hours if refrigerated.

TAZOCIN should not be mixed with other drugs in a syringe or infusion bottle since compatibility has not been established.

AVAILABILITY OF DOSAGE FORMS

TAZOCIN (Sterile Piperacillin Sodium Powder and Tazobactam Sodium) is available in glass vials in the following dosage forms:⁴⁵

TAZOCIN 2.25 g vial: Provides piperacillin sodium equivalent to 2 grams of piperacillin and tazobactam sodium equivalent to 0.25 gram of tazobactam.
2.25g vial - 10 per box.

TAZOCIN 3.375 g vial: Provides piperacillin sodium equivalent to 3 grams of piperacillin and tazobactam sodium equivalent to 0.375 gram of tazobactam.
3.375g vial - 10 per box.

TAZOCIN 4.5 g vial: Provides piperacillin sodium equivalent to 4 grams of piperacillin and tazobactam sodium equivalent to 0.5 gram of tazobactam.
4.5g vial - 10 per box.

TAZOCIN 110 µg sensitivity discs (100 µg piperacillin + 10 µg tazobactam) are available and must be refrigerated upon receipt.

MICROBIOLOGY

Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis. In vitro, piperacillin is active against a variety of gram-positive and gram-negative aerobic and anaerobic bacteria. Tazobactam sodium, which has very little intrinsic microbiologic activity due to its very low level of binding to penicillin-binding proteins, is a β -lactamase inhibitor of the Richmond-Sykes class III (Bush class 2b & 2b') penicillinases and cephalosporinases. It varies in its ability to inhibit class II and IV (2a & 4) penicillinases. Tazobactam does not induce chromosomally-mediated β -lactamases at tazobactam levels achieved with the recommended dosing regimen.

There are important variables affecting the therapeutic effectiveness or the results of the susceptibility testing of an antibiotic, ie, concentration of the bacterial inoculum, pH of the medium or body site, serum binding or media supplementation with sera and the test methodology.

Effects of the Inoculum Size:

The presence of tazobactam reduces the marked inoculum effect observed with piperacillin against Enterobacteriaceae and Haemophilus influenzae. Against strains of the Bacteroides fragilis group, piperacillin/tazobactam showed an intermediate inoculum effect. The effect was observed at inoculums of 10^8 cfu/mL and affected mostly the bactericidal activity of the β -lactam/inhibitor combination.

Effect of pH:

The activity of piperacillin/tazobactam against most microorganisms is not adversely affected by a pH down to 5.5. However, some strains will be less susceptible (approximately four fold increase in the MIC) at pH of 5.5.

Effect of Serum:

Both piperacillin and tazobactam bind to plasma proteins. However, this binding did not appear to affect the results of susceptibility testing (MIC) if the test media was supplemented with 5% human serum.

Effect of Test Methodology or the Test Medium:

Zone sizes obtained on DST (Diagnostic Sensitivity Test) and Iso-Sensitest agars showed similar zone sizes for 1450 paired sets of assays (96.1% of the 1450 strains showed agreement within 3 mm).

MIC results of piperacillin/tazobactam tested by the NCCLS agar and broth dilution methods were not significantly different; the mean piperacillin/tazobactam MICs were 3.2 and 3.3 µg/mL for the agar broth micro dilution test, respectively.

Table 1 provides a summary of the in vitro activities of piperacillin and piperacillin/tazobactam against a number of clinical isolates.

TABLE 1
THE IN VITRO ACTIVITIES OF PIPERACILLIN AND PIPERACILLIN/TAZOBACTAM AGAINST CLINICAL ISOLATES^(a)
OF VARIOUS GRAM-POSITIVE AND GRAM-NEGATIVE AEROBIC AND ANAEROBIC SPECIES

Organism	No. Strains	Drug	MIC ₅₀ (ug/ml)	MIC ₉₀ (ug/ml)	Distribution of Isolates at Indicated Concentration (ug/ml)											
					≤ 0.12	0.25	0.5	1	2	4	8	16	32	64	128	≥ 256
<u>Gram-Negative</u>																
Acinetobacter spp.	77	P	16	128												
	77	PT4 ^(b)	4	32	12	4	2	3	8	12	15	13	9	3	6	4
Branhamella catarrhalis	25	P	0.25	1	12	3		9				1				
	25	PT4	≤0.125	≤0.125	23		1				1					
Citrobacter diversus	20	P	8	16		1				4	9	4	1			1
	20	PT4	2	4	1			3	8	6	1	1				
Citrobacter freundii	43	P	4	128				1	15	12	5	1	2		4	3
	43	PT4	2	32	1			7	19	11			1	2	1	1
Enterobacter aerogenes	44	P	4	64				2	15	17		2	2	3	3	
	44	PT4	4	32				3	14	16	1	3	6	1		
Enterobacter cloacae	140	P	2	>128			1	17	55	36	4	1	3	1	8	14
	140	PT4	2	128	1		4	23	61	24	2	3	7	1	10	4
Enterobacter spp.	14	P	2	16				3	5	2	2	1				1
	14	PT4	2	8			1	3	4	3	3					
Escherichia coli	797	P	2	>128	1	1	8	178	340	59	12	17	26	16	30	109
	797	PT4	2	4	14	9	56	314	311	49	18	11	5	3	2	5
Haemophilus influenzae	139	P	≤0.125	16	90	2	4	22	4		3	1	1	1	1	10
	138	PT4	≤0.125	≤0.125	130	3	2		2	1						
Haemophilus spp.	39	P	≤0.125	2	20	3	3	9	1	2			1			
	39	PT4	≤0.125	0.5	28	6	2	2	1							
Klebsiella spp.	98	P	8	32				2	11	24	34	15	4	4	1	3
	98	PT4	2	4		4	2	22	51	12	5				1	1
(continued)																

TABLE 1 (cont'd)

Organism	No. Strains	Drug	MIC ₅₀ (ug/ml)	MIC ₉₀ (ug/ml)	Distribution of Isolates at Indicated Concentration (ug/ml)											
					≤ 0.12	0.25	0.5	1	2	4	8	16	32	64	128	≥ 256
<u>Gram-Negative</u>																
Klebsiella pneumoniae	256	P	8	128				4	16	81	87	24	11	2	7	24
	256	PT4	2	8	3	2	5	27	97	86	11	12	5	2	1	5
Proteus indole negative	156	P	1	4	5	37	27	65	4	3	6	2	2	1	1	3
	156	PT4	0.25	0.5	20	73	49	8	1	4		1				
Proteus indole positive	59	P	1	32	2	5	8	28	4	4	1		2	4		1
	59	PT4	0.25	0.5	17	25	12	3	2							
Providencia spp.	13	P	2	64		1	1	4	2	1			1	2		1
	13	PT4	1	8		2	3	2	3	1	1	1	1			
Pseudomonas aeruginosa	313	P	4	64		2	3	7	34	129	55	33	16	13	10	11
	312	PT4	4	32	2	5	6	3	46	143	50	24	14	5	5	9
Pseudomonas spp.	24	P	2	16			2	6	6	6	1	2	1			
	25	PT4	2	16	8		1	3	2	7	1	2				1
Serratia spp.	53	P	2	64				10	18	11	5	2	1	1	1	4
	53	PT4	2	8		2	6	10	19	10	3	2		1		
Other Gram-Negative Rods	31	P	1	2	9	3	3	12	1			3				
	31	PT4	0.25	1	15	4	6	3	1		1	1				
Xanthomonas maltophilia	43	P	>128	>128					1			3	3	4	10	22
	43	PT4	64	>128				1		1	1	10	6	4	4	16
<u>Gram-Positive</u>																
Corynebacterium spp.	19	P	1	>128	3	1	1	6	1	1	3			1		2
	19	PT4	0.5	>128	7	2	3		1	2	1		1			2
Enterococcus faecalis	277	P	4	4	2	1	1	30	58	170	8	2	1	1	2	1
	258	PT4	4	4	3	4	3	37	78	119	8	2	1	1		2
Enterococcus faecium	31	P	8	>128	2	1		2	1	7	5	3	2	1	3	4
(continued)	28	PT4	8	>128	2	1		1	1	6	5	3	1	2	2	4

TABLE 1 (cont'd)

Organism	No. Strains	Drug	MIC ₅₀ (ug/ml)	MIC ₉₀ (ug/ml)	Distribution of Isolates at Indicated Concentration (ug/ml)											
					≤ 0.12	0.25	0.5	1	2	4	8	16	32	64	128	≥ 256
<u>Gram-Positive</u>																
Enterococcus spp.	65	P	4	32	1		1	7	17	26	3	1	4		1	4
	27	PT4	4	128	2			4	3	9	2	1	3		1	2
Other Gram-Positive Rods	19	P	1	2	1	2	5	7	3				1			
	19	PT4	1	2	2	4	3	8	1				1			
Staphylococcus aureus	487	P	4	64	2		11	90	54	113	65	61	33	21	19	18
	475	PT4	1	2	7	13	62	229	135	25	3			1		1
Staphylococcus coag. negative	203	P	1	8	4	22	24	69	37	25	12	7	2			
	201	PT4	0.5	2	40	49	45	46	17	3	1					
Streptococcus Group A	50	P	0.25	1	22	4	1	23								
	50	PT4	≤0.125	≤0.125	48	1	1									
Streptococcus Group B	92	P	0.5	1	16	27	16	32	1							
	91	PT4	0.25	0.5	28	34	21	8								
Streptococcus pneumoniae	149	P	≤0.125	1	109	6	2	30	1			1				
	149	PT4	≤0.125	≤0.125	135	5	5	2		2						
Streptococcus spp.	256	P	0.25	2	111	27	6	85	12	8	2	2			1	2
	256	PT4	≤0.125	1	175	35	15	10	9	3	4	1	1		1	2
<u>Anaerobes</u>																
Bacteroides fragilis group	338	P	8	64			1	9	39	65	65	65	47	16	11	20
	339	PT4	1	8	70	37	32	37	42	52	52	11	5		1	
Bacteroides pigmented.	36	P	1	16	6	3	2	8	2	5	4	4	2			
	36	PT4	≤0.125	2	28	1	1	2	4							
Bacteroides spp.	101	P	4	16	7	4	6	17	9	13	14	21	8	2		
	101	PT4	≤0.125	2	76	5	1	5	6	4	4					
Clostridium perfringens	36	P	≤0.125	1	20	4		12								
	36	PT4	≤0.125	≤0.125	33	2		1								
(continued)																

TABLE 1 (cont'd)

Organism	No. Strains	Drug	MIC ₅₀ (ug/ml)	MIC ₉₀ (ug/ml)	Distribution of Isolates at Indicated Concentration (ug/ml)											
					≤ 0.12	0.25	0.5	1	2	4	8	16	32	64	128	≥ 256
<u>Gram-Positive</u>																
Clostridium spp.	24	P	1	8	6	1	2	6	2	4	1	1			1	
	24	PT4	1	8	8	2	2	3	4	2	2	1				
Fusobacterium spp.	25	P	≤0.125	4	15	2	1	3		3				1		
	25	PT4	≤0.125	4	20	1		1		2		1				
Miscellaneous Anaerobes	19	P	0.5	16	6	3	3	4			1	1				1
	19	PT4	≤0.125	2	10	2	2	2	2			1				
Misc. Anaerobic Gram-Positive Rods	37	P	1	16	11	3	2	12	2			6	1			
	37	PT4	≤0.125	16	22	3	3	4			1	3	1			
Peptostreptococcus	166	P	≤0.125	1	97	8	4	45	1	2	7	2				
	166	PT4	≤0.125	0.5	138	10	4	4	1	2	6	1				

(a) Isolates from patients enrolled in clinical evaluation studies of piperacillin/tazobactam in North America and Europe.

(b) MICs are expressed as concentration of piperacillin in the presence of the 4 ug/ml of tazobactam.

Susceptibility Tests

Measurement of MIC or MBC and achieved antimicrobial compound concentrations may be appropriate to guide therapy in some infections. (See CLINICAL PHARMACOLOGY section for further information on drug concentrations achieved in infected body sites and other pharmacokinetic properties of this antimicrobial drug product.)

Diffusion techniques:

Quantitative methods that require measurement of zone diameters provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The NCCLS standardized procedure has been recommended for use with disks to test the susceptibility of microorganisms to piperacillin/tazobactam uses the 100 µg/10 µg piperacillin/tazobactam disk. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for piperacillin/tazobactam.

Reports from the laboratory giving results of the standard single-disk susceptibility test with a 100 µg/10 µg piperacillin/tazobactam disk should be interpreted according to the following criteria:

For Enterobacteriaceae:

<u>Zone Diameter (mm)</u>	<u>Interpretation</u>
≥ 21	Susceptible (S)
18 - 20	Intermediate (I)
≤ 17	Resistant (R)

For Haemophilus species:

<u>Zone Diameter (mm)</u>	<u>Interpretation</u>
≥ 27	Susceptible (S)
≤ 26	Resistant (R)

For *Pseudomonas aeruginosa*:

<u>Zone Diameter (mm)</u>	<u>Interpretation</u>
≥ 18	Susceptible (S)
≤ 17	Resistant (R)

For *Staphylococcus* species:

<u>Zone Diameter (mm)</u>	<u>Interpretation</u>
≥ 20	Susceptible (S)
≤ 19	Resistant (R)

A report of "Susceptible" indicates that the pathogen is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in the blood. A report of "Intermediate" indicates that the result should be considered equivocal and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and other therapy should be selected.

Standardized susceptibility test procedures require the use of laboratory control microorganisms.

The 100 µg/10 µg piperacillin/tazobactam disk should give the following zone diameters in these laboratory test quality control strains:

<u>Microorganism</u>	<u>Zone Diameter (mm)</u>
Escherichia coli ATCC 25922	24 - 30
Escherichia coli ATCC 35218	25 - 31
Pseudomonas aeruginosa ATCC 27853	25 - 33
Haemophilus influenzae ATCC 49247	32 - 36

Dilution techniques:

Quantitative methods that are used to determine minimum inhibitory concentrations provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure (NCCLS, Method for dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically) uses a dilution method (broth, agar, or microdilution) or equivalent with piperacillin/tazobactam lyophilized powder. The MIC values obtained should be interpreted according to the following criteria:

For Enterobacteriaceae:

<u>MIC (µg/mL)</u>	<u>Interpretation</u>
≤ 16	Susceptible (S)
32 - 64	Intermediate (I)
≥ 128	Resistant (R)

For *Pseudomonas aeruginosa*

<u>MIC (µg/mL)</u>	<u>Interpretation</u>
≤ 64	Susceptible (S)
≥ 128	Resistant (R)

For *Haemophilus* species:

<u>MIC (µg/mL)</u>	<u>Interpretation</u>
≤ 1	Susceptible (S)
≥ 2	Resistant (R)

For *Staphylococcus* species:

<u>MIC (µg/mL)</u>	<u>Interpretation</u>
≤ 8	Susceptible (S)
≥ 16	Resistant (R)

Interpretation is as stated above for results using diffusion techniques.

As with standard diffusion techniques, dilution methods require the use of laboratory control microorganisms. Standard piperacillin/tazobactam (8:1) lyophilized powder should provide the following MIC values:

<u>Microorganism</u>	<u>MIC (µg/mL)</u>
<i>Escherichia coli</i> ATCC 25922	1 - 4
<i>Escherichia coli</i> ATCC 35218	2 - 8
<i>Pseudomonas aeruginosa</i> ATCC 27853	1 - 8
<i>Staphylococcus aureus</i> ATCC 29213	1 - 4
<i>Haemophilus influenzae</i> ATCC 49247	0.06 - 0.25

Anaerobic techniques:

For anaerobic bacteria, the susceptibility to piperacillin/tazobactam can be determined by the reference agar dilution method or by alternate standardized test methods.

For Bacteroides species, the dilution and zone diameters should be interpreted as follows:

MIC (µg/mL) Zone Diameter (mm) Interpretation

≤ 16	≥ 21	Susceptible (S)
≥ 32	≤ 20	Resistant (R)

As with standard diffusion techniques, dilution methods require the use of laboratory control microorganism. Standard piperacillin/tazobactam lyophilized powder should provide the following MIC values:

<u>Micro-organism</u>	<u>MIC (µg/mL)</u>
Bacteroides fragilis ATCC 25285	1 - 4

PHARMACOLOGY

Animal Pharmacology:

Enzyme Induction:

Hepatic mixed function oxidase studies in the rat and dog indicated that tazobactam did not induce the hepatic drug metabolizing enzymes in these species.

Toxicokinetics:

Evaluation of the pharmacokinetic disposition of tazobactam and piperacillin following dose administration disclosed no evidence of alteration in the disposition of either agent. Plasma concentrations of tazobactam following intraperitoneal administration, the route of administration in rat toxicity studies, were proportional to the dose increment from 20 to 500 mg/kg. Similarly, plasma concentrations of piperacillin were dose proportional up to 1000 mg/kg but were greater than dose proportional at higher doses.

In pharmacokinetics studies, as well as in the acute and long-term rat and dog toxicity studies, the extent of piperacillin and tazobactam exposure was much higher than that observed in man. The disposition of tazobactam in the rat differed considerably from the disposition in the dog and man, with the dog closely resembling man in the extent of distribution, elimination half-life, and systemic clearance of tazobactam.

Both species employed in the safety assessment studies (rat, dog) produced a metabolite

(M-1) from tazobactam. Plasma concentrations of M-1 following single IV doses of 25, 150, and 400 mg/kg of M-1 were dose proportional.

Placental Transfer:

The penetration of tazobactam and its metabolites through the placental barrier was moderate in pregnant rats. Tazobactam and its metabolites initially attained concentrations in the uterus, placenta, ovary, and amnion that were 20-50% of the plasma concentrations, while concentrations attained in the fetus were about 3%.

Excretion in Breast Milk:

Although drug related concentrations of radioactivity were detected in milk of lactating rats, the concentrations of unchanged tazobactam in pup plasma and tissues were very low.

The effects seen in these studies with piperacillin/tazobactam are similar to those seen with other β -lactam antibiotics in combination with β -lactamase inhibitors. Results of preclinical studies support the use piperacillin/tazobactam in patients with infectious diseases.

Human Pharmacology:

Pharmacokinetics

Peak plasma concentrations of tazobactam and piperacillin are attained immediately after completion of an intravenous infusion of TAZOCIN. Piperacillin plasma concentrations, following a 30 minute infusion of TAZOCIN are similar to those obtained when equivalent

doses of piperacillin are administered alone, with mean peak plasma concentrations of approximately 134, 242, and 298 $\mu\text{g/mL}$ for the 2 g/0.25 g, 3 g/0.375 g and 4 g/0.5 g (piperacillin/tazobactam) doses, respectively. The corresponding mean peak plasma concentrations of tazobactam are 15, 24 and 34 $\mu\text{g/mL}$.

After 3 g/0.375 g (piperacillin/tazobactam) 30 minute IV infusions administered every 6 hours, steady state plasma concentrations of tazobactam and piperacillin are similar to those obtained after the first dose. In like manner, after 4 g/0.5 g or 2 g/0.25 g piperacillin/tazobactam 30 minute infusions given every 6 hours, from those obtained after the first dose. Steady state plasma concentrations after 30 minute infusions every 6 hours are provided in Table 2(A,B), respectively.

TABLE 2(A,B)

**STEADY STATE MEAN PLASMA CONCENTRATIONS IN ADULTS
AFTER 30-MINUTE INTRAVENOUS INFUSION OF
PIPERACILLIN/TAZOBACTAM EVERY 6 HOURS**

A) TAZOBACTAM

Dose*	PLASMA CONCENTRATIONS ($\mu\text{g/mL}$)						AUC ($\mu\text{g}\cdot\text{hr/mL}$)
	30 min	1 hr	2 hr	3 hr	4 hr	6 hr	AUC 0-6
2 g/0.25	14.8 (14)	7.2 (22)	2.6 (30)	1.1 (35)	0.7 (6) ^b	<0.5	16.0 (21)
3 g/0.375 g	24.2 (14)	10.7 (7)	4.0 (18)	1.4 (21)	0.7 (16) ^a	<0.5	25.0 (8)
4.g/0.5 g	33.8 (15)	17.3 (16)	6.8 (24)	2.8 (25)	1.3 (30)	<0.5	39.8 (15)

* piperacillin/tazobactam

a N=4

b N=3

B) PIPERACILLIN

Dose*	PLASMA CONCENTRATIONS ($\mu\text{g/mL}$)						AUC ($\mu\text{g}\cdot\text{hr/mL}$)
	30 min	1 hr	2 hr	3 hr	4 hr	6 hr	AUC 0-6
2 g/0.25 g	134 (14)	57 (14)	17.1 (23)	5.2 (32)	2.5 (35)	0.9 (14) ^a	131 (14)
3 g/0.375	242 (12)	106 (8)	34.6 (20)	11.5 (19)	5.1 (22)	1.0 (10)	242 (10)
4 g/0.5 g	298 (14)	141 (19)	46.6 (28)	16.4 (29)	6.9 (29)	1.4 (30)	322 (16)

* piperacillin/tazobactam

a N=4

24 (2.25 g and 4.5 g and 22 (3.75g) subjects were enrolled in the study and all were evaluable for pharmacokinetic analysis.

In healthy subjects, following single or multiple TAZOCIN doses, the plasma half-lives of tazobactam and piperacillin range from 0.7 to 1.2 hours and are unaffected by dose or duration of infusion.

Bioavailability

Twelve, healthy, male volunteers were given a single IM injection of 2 g piperacillin/0.25 g tazobactam to determine absolute bioavailability. Within one hour peak plasma concentrations of 125 $\mu\text{g/mL}$ and 15.6 $\mu\text{g/mL}$ for piperacillin and tazobactam, respectively, were attained. The absolute bioavailability (F) was 71% for piperacillin and 84% for tazobactam.

Distribution

The distribution volume at steady-state (V_{ss}) for tazobactam ranged from 12.8 to 15.8 L following 30 minute infusion dose of 0.1 to 1.0 g. Coadministration of piperacillin significantly decreased tazobactam V_{ss} by approximately 16%. Piperacillin V_{ss} (range 12 to 17

L) following a 30 minute infusion dose of 4 g was unaffected by tazobactam. In studies using radio-labelled tazobactam the blood to plasma concentration ratios of radioactivity were approximately 0.5 to 0.8 at each sampling time suggesting that tazobactam and its metabolite do not preferentially distribute into the cellular components of blood.

After a 30 minute IV infusion of piperacillin/tazobactam to subjects undergoing elective surgery, both compounds were well distributed into tissues with mean tissue concentrations generally 50 to 100% of plasma concentrations. Tissue concentrations of tazobactam and piperacillin were generally greater than 19 and 6 $\mu\text{g/g}$, respectively, in lung, intestinal mucosa, gallbladder, and appendix for up to 2.5 hours after a dose of either 0.5 g/4 g or 0.5 g/2 g piperacillin/tazobactam. Similarly, after a 2 g/0.5 g piperacillin/tazobactam dose, concentrations up to 3.5 hours after dosing were greater than 5.6 $\mu\text{g/g}$ for piperacillin and 3.7 $\mu\text{g/g}$ for tazobactam in intestine, gallbladder and stomach mucosa.

A dose of 4 g piperacillin/0.5 g tazobactam produced peak concentrations of 94.2 $\mu\text{g/g}$ for piperacillin and 7.7 $\mu\text{g/g}$ for tazobactam in skin. Concentrations in bile from gallbladder aspirates ranged from 1.3 to 42.9 $\mu\text{g/mL}$ for tazobactam and from 220 to 1045 $\mu\text{g/mL}$ for piperacillin after an infusion dose of 3 g piperacillin/0.375 g tazobactam. Following a 4 g piperacillin/0.5 g tazobactam 30 minute infusion, peak blister levels of tazobactam and piperacillin were 11.3 and 77.2 $\mu\text{g/mL}$, respectively. The blister fluid AUC was, on average, about 90% of the plasma AUC for either compound. As seen with other penicillins,

concentrations in cerebral spinal fluid are low. They reached 2 to 3% of plasma values, 2 hours after start of a 5 g piperacillin/0.625 g tazobactam 30 minute infusion.

Dose Proportionality

To investigate the change in C_{\max} with increasing dosage, two single dose studies, involving 32 healthy volunteers, were performed using doses of 2 g/0.25 g, 3 g/0.375 g, 4 g/0.5 g piperacillin/tazobactam given as either a 5 minute infusion or a 30 minute infusion. For both compounds, the increase in C_{\max} was proportional. AUC was proportional between the 3 g/0.375 g and 4 g/0.5 g piperacillin/tazobactam doses. However, increases in AUC were more than proportional (up to 30%) as the dose increased from 2 g/0.25 g to 3 g/0.375 g or 4 g/0.5 g piperacillin/ tazobactam.

Metabolism and Excretion

Piperacillin undergoes biotransformation in the gastrointestinal tract, where minor (<1% total dose) microbiologically inactive metabolites are formed via bacterial hydrolysis.

Tazobactam is metabolized to a single metabolite (M1) which lacks pharmacological and antibacterial activities and circulates at approximately 10% of the parent concentrations in subjects with normal renal function. Following an IV infusion of 3 g piperacillin and 0.377 g ^{14}C -tazobactam (60 microcuries), tazobactam was excreted about 80% as unchanged drug and the remainder as M1. Up to 4 hours post-dose, total radioactivity concentrations in plasma could be accounted for by unchanged tazobactam and M1 while, after 4 hours, they are primarily accounted for by M1.

Piperacillin from TAZOCIN is eliminated by renal pathways, and recovery of piperacillin from TAZOCIN in bile is < 1% (HPLC assay) of the dose administered. About 50% - 70% of the dose is excreted unchanged by the kidney. The excretion is unaffected by coadministration of tazobactam. Urine concentrations of piperacillin from TAZOCIN generally exceeded 1500 µg/mL over the dosing interval following a 30 minute IV infusion of 3 g piperacillin/0.375 tazobactam.

Tazobactam and its M1 metabolite are eliminated primarily by renal excretion. The magnitude of renal clearance of each compound suggests renal excretion is via glomerular filtration and net active tubular secretion. Urinary excretion of tazobactam is decreased in the presence of piperacillin, presumably due to competition for renal tubular secretion. Urinary concentrations generally exceeded 200 µg/mL over the dosing interval after a 30 minute IV infusion of 3 g piperacillin/0.375 g tazobactam.

Following an IV infusion of 3 g piperacillin and 0.375 g tazobactam (60 microcuries), recovery of total radioactivity in urine and feces over the 5 day collection period was 94%. The majority (84%) of the radioactivity was recovered in urine within 6 hours postdose. Fecal recovery of radioactivity was <1% of the dose.

Protein Binding

In humans, the protein binding of piperacillin was < 20% and tazobactam was < 5%. This was essentially constant over the therapeutic range. The binding of both tazobactam and piperacillin was not affected by the presence of the other compound. The protein binding of M1 was negligible (< 3%) in human plasma.

Elimination Half-Life

In healthy subjects, following single or multiple doses, the plasma elimination $T_{1/2}$ of tazobactam and piperacillin ranged from 0.7 to 1.2 hours and was independent of dose level and duration of infusion. Given concomitantly, piperacillin $T_{1/2}$ was unchanged, whereas an increase of about 18% in tazobactam $T_{1/2}$ was observed. Following an IV infusion of 3 g piperacillin and 0.377 g ^{14}C -tazobactam (60 microcuries), the $T_{1/2}$ of total radioactivity in plasma was 3.2 hours reflecting the elimination of M1.

Renal/Hepatic Impairment

Mean plasma concentrations of piperacillin and tazobactam in subjects with decreased renal impairment are shown in Table 3(A,B). With decreasing renal function from $\text{CL}_{\text{cr}} >90$ to <20 mL/min., peak plasma concentrations of both piperacillin and tazobactam increased approximately 30%, while the mean C_{max} of the M1 metabolite increased about 4-fold. Plasma clearance of piperacillin and tazobactam was decreased (up to 2.7- and 4.4-fold, respectively) and $T_{1/2}$ increased (up to 2- and 4-fold, respectively) as renal function decreased. Dosage regimen adjustments are recommended at $\text{CL}_{\text{cr}} <40$ mL/min.

TABLE 3(A,B)

**MEAN PLASMA CONCENTRATION IN SUBJECTS WITH DECREASED
RENAL FUNCTION FOLLOWING A 30 MINUTE INTRAVENOUS INFUSION**

A) TAZOBACTAM

Creatinine Clearance	Time (hour)								
	0.5	1	2	3	4	6	8	12	24
>90	23.6	12.5	5.2	2.3	1.3	BQL	BQL	BQL	BQL
60-90	29.4	16.7	8.1	4.7	3.0	1.6	BQL	BQL	BQL
40-59	31.5	19.5	11.0	7.3	4.9	2.4	1.6	BQL	BQL
20-39	28.8	21.1	14.9	10.6	7.6	4.0	2.2	1.4	BQL
<20	31.5	24.4	18.2	14.7	12.1	8.2	5.4	3.3	2.3

B) PIPERACILLIN

Creatinine Clearance	Time (hours)								
	0.5	1	2	3	4	6	8	12	24
>90	209	96.3	35.8	15.0	7.2	2.1	1.2	BQL	BQL
60-90	235	138	57.2	27.8	15.0	4.7	1.1	BQL	BQL
40-59	288	154	80.0	45.4	27.0	9.2	3.8	1.4	BQL
20-39	245	165	92.1	53.9	30.6	10.4	4.1	1.5	BQL
<20	253	179	120.0	84.3	56.3	28.8	15.9	6.0	1.4

Hemodialysis removed approximately 30 to 40% of the piperacillin and tazobactam doses, M1 was removed from the systemic circulation similarly to tazobactam. To maintain pre-dialysis plasma concentrations an additional one-third of the piperacillin/tazobactam unit dose is recommended following hemodialysis therapy. On average, peritoneal dialysis removed up to 6% and 21% of the dose for piperacillin and tazobactam with up to 16% of the tazobactam dose removed as M1. For dosage recommendations for patients undergoing hemodialysis, see DOSAGE AND ADMINISTRATION.

The single dose pharmacokinetic profiles of piperacillin and tazobactam are affected by cirrhosis with significantly lower CL_T (29%) and longer $T_{1/2}$ (25%) for piperacillin. Similar changes in tazobactam CL_T (25%) and $T_{1/2}$ (18%) were observed, although only the difference in CL_T was significant. Since the predicted steady-state plasma concentrations of both compounds after multiple dosing were only 10% different between cirrhotic and normal subjects, no adjustment in dosage regimen is recommended due to cirrhosis.

Drug Interactions

Probenecid, tobramycin and vancomycin were investigated for potential pharmacokinetic interaction with piperacillin/tazobactam.

Coadministration of a 1 g oral dose of probenecid did not significantly change C_{max} but lowered CL_R (20 to 25%) and increased $T_{1/2}$ for piperacillin by 21% and tazobactam by 71%.

Coadministration of probenecid did not result in any significant increase in the plasma concentration of piperacillin/tazobactam.

Vancomycin (500 mg) given as a 60 minute infusion prior to piperacillin/tazobactam did not significantly change the pharmacokinetic profiles for either piperacillin or tazobactam.

Similarly, no significant change in vancomycin pharmacokinetics was observed.

These studies indicate that adjustment in dosage regimen for piperacillin/tazobactam, tobramycin or vancomycin is not warranted when these compounds are coadministered.

Neutropenic

In neutropenic subjects, after 30 minute infusions of 3 g piperacillin/0.375 g tazobactam every 4 hours for 5 days, the elimination $T_{1/2}$ was 40 to 80% longer and CL_T was 20 to 40% lower for both piperacillin and tazobactam. After multiple dosing, the mean C_{max} and AUC_{0-4} values were about 40% higher than after the first dose. However, this difference is not large enough to warrant adjustment of the dosage regimen in neutropenic patients.

TOXICOLOGY

Acute Toxicity

In mice (10/sex), IV doses of 2000:500 mg/kg of piperacillin:tazobactam resulted in no mortality and no signs of toxicity or treatment-related effects while 4000:1000 mg/kg of piperacillin:tazobactam resulted in death in 1 of 10 male mice and 5 of 10 female mice within 6 hours after dosing. At this dose, muscular hypertonia, tachypnea and convulsions were observed. In mice, IV doses of 4500:562.5 mg/kg of piperacillin:tazobactam resulted in death of 2 of 10 males within 6 hours and 3 of 10 females (2 females died 2 days and 1 female died 7 days after dosing). At this dose, shallow and frequent respiration, muscular hypertonia, reduced mobility and convulsions were observed. In mice (10/sex), IV doses of tazobactam up to 3500 mg/kg resulted in no mortality and no signs of toxicity or treatment related effects while an IV piperacillin dose of 4500 mg/kg in mice resulted in death in 4 of 10 females within 6 hours after dosing. At this dose, shallow and frequent respiration, muscular hypertonia, reduced mobility and convulsions were observed. In 1 of 10 male mice, the right kidney was white in colour. In addition, partial papillary necrosis and partial tubular necrosis of the cortex accompanied by mononuclear leucocyte infiltration were observed.

In rats, IV doses of piperacillin:tazobactam resulted in death in 7 of 10 females at 2000:250 mg/kg, in 3 of 10 males at 2200:275 mg/kg, and in 10 of 10 males and 9 of 10 females at 2400:300 mg/kg, within 6 hours after dosing. In rats dosed IV, shallow and frequent respiration, muscular hypertonia, staggering, and convulsions were observed. Following administration of IP doses of 4000:1000 mg/kg of tazobactam:piperacillin, there was no mortality. At this IP dose, transient wet perianal area and decreased body-weight gain and food consumption in male rats occurred during the first week after dosing. Distended cecum occurred in two females.

In rats, IV doses of piperacillin resulted in death in 8 of 10 females at 1000 mg/kg (bid), 4 of 10 males and 8 of 10 females at 2200 mg/kg, and 8 of 10 males and 9 of 10 females at 2400 mg/kg, within 6 hours after dosing. At these doses, shallow and frequent respiration, muscular hypertonia, staggering and convulsions occurred. Following administration of IP doses of 5000 mg/kg of tazobactam, there was no mortality. At this dose, transient wet perianal area and decreased body-weight gain and food consumption in male and/or female rats occurred during the first week after dosing.

In dogs (1/sex), IV doses resulted in salivation at 2600:330 mg/kg of piperacillin:tazobactam; emesis, salivation and conjunctival congestion at 4000:500 mg/kg of piperacillin:tazobactam; and death in 1 male and 1 female within 2 hours after dosing at 5200:650 mg/kg of piperacillin:tazobactam.

In dogs, IV doses of tazobactam at 3000 or 5000 mg/kg resulted in no deaths. At these doses, erythema, edema, emesis, loose stools, slight changes in hematology (decreased red blood cell

parameters, platelets and lymphocytes) and in serum chemistry (decreased potassium and increased AST) parameters occurred. In addition, salivation occurred at 3000 mg/kg of tazobactam and decreased motor activity occurred at 5000 mg/kg of tazobactam. An IV dose of 5200 mg/kg of piperacillin resulted in no deaths. At this dose, emesis and salivation occurred.

Long-Term Toxicity

Long-term toxicity studies in the rat and dog established target organ toxicity. In both species, altered hepatocellular glycogen distribution, a well-known effect of β -lactamase inhibitors, was observed. This finding occurred in drug-treated rats in 5-day, 1-,3-, and 6-month studies at doses ≥ 80 mg/kg/day of tazobactam alone or in combination with piperacillin. In dogs, it occurred with tazobactam alone or in combination with piperacillin at 3000 mg/kg/day for 5 days, ≥ 40 mg/kg/day for 1 and 3 months and ≥ 80 mg/kg/day for 6 months. Additionally, enlarged ceca were observed in rats. Enlarged ceca, caused by suppression of intestinal microflora, is a non-specific effect of antimicrobials in rodents. Other drug-related effects observed in rats and dogs in long-term toxicity studies were decreased red blood cell parameters and decreased cholesterol and serum triglycerides.

Decreased platelets and total protein, and increased alkaline phosphatase, ALT, and AST were also seen in dogs. The effect on red blood cell parameters, cholesterol and triglyceride levels, and altered distribution of hepatocellular glycogen were reversible or diminished following a recovery period.

Reproductive Toxicology

Tazobactam alone or in combination with piperacillin did not affect fertility in rats. IP doses of tazobactam or piperacillin:tazobactam caused adverse changes in reproductive performance of F₀ generation only at doses greater than or equal to 160:40 mg/kg/day piperacillin:tazobactam that caused maternal toxicity (decreased food consumption and/or body weights). The F₁ and F₂ generations were unaffected.

IV doses up to 3000 mg/kg/day of tazobactam and 3000:750 mg/kg/day piperacillin:tazobactam were not teratogenic in mice or rats. Postnatal growth and development, behaviour and reproductive performance of the F₁ generation were unaffected by in utero exposure of rats to tazobactam alone or in combination with piperacillin. Mortality in rats was caused by a rapid injection rate of piperacillin or piperacillin/tazobactam but is not relevant to clinical usage.

Perinatal and Postnatal Toxicity

In rats, IP doses of tazobactam and piperacillin/tazobactam caused effects on perinatal growth and postnatal growth and development at doses (320 mg/kg/day of tazobactam and 640:160 mg/kg/day of piperacillin:tazobactam) that caused maternal toxicity (decreased food consumption and/or body weight gain).

Carcinogenicity, Mutagenicity, Impairment of fertility

Longterm studies in animals to evaluate carcinogenic potential have not been performed with tazocin, piperacillin or tazobactam.

Piperacillin/tazobactam was negative in microbial mutagenicity assays at concentrations up to 14.84/1.86 mcg/plate. Piperacillin/tazobactam was negative in the unscheduled DNA synthesis

(UDS) test at concentrations up to 5689/711 mcg/mL. Piperacillin/tazobactam was negative in a mammalian point mutation (Chinese hamster ovary cell HPRT) assay at concentration up to 8000/1000 mcg/mL. Piperacillin/tazobactam was negative in a mammalian cell (BALB/c-3T3) transformation assay at concentrations up to 8/1 mcg/mL. In vivo, piperacillin/tazobactam did not induce chromosomal aberrations in rats dosed IV with 1500/187.5 mg/kg; this dose is similar to the maximum recommended human daily dose on a body-surface-area basis (mg/m^2).

Piperacillin: Piperacillin was negative in microbial mutagenicity assays at concentrations up to 50 mcg/plate. There was no DNA damage in bacteria (Rec assay) exposed to piperacillin at concentrations up to 200 mcg/disc. Piperacillin was negative in the UDS test at concentrations up to 10,000 mcg/mL, which is 26 times the human plasma concentration of piperacillin. In mammalian point mutation (mouse lymphoma cells) assay, piperacillin was positive at concentrations ≥ 2500 mcg/mL, which is 7 times the human plasma concentration. Piperacillin was negative in a cell (BALB/c-3T3) transformation assay at concentrations up to 3000 mcg/mL, which is 8 times the human plasma concentration. In vivo, piperacillin did not induce chromosomal aberrations in mice at IV doses up to 2000 mg/kg/day or rats at IV doses up to 1500 mg/kg/day. These doses are 6 (mice) and 4 (rats) times the maximum recommended human daily dose based on body weight, and half (mice) or similar to (rats) the human dose based on body-surface area (mg/m^2). In another in vivo test, there was no dominant lethal effect when piperacillin was given to rats at IV doses up to 2000 mg/kg/day, which is similar to the human dose based on body-surface area. When mice were given piperacillin at IV doses up to 2000 mg/kg/day, which is half the human dose based on body-surface area (mg/m^2), urine from these animals was not mutagenic when tested in a microbial mutagenicity assay. Bacteria

injected into the peritoneal cavity of mice given piperacillin at IV doses up to 2000 mg/kg/day did not show increased mutation frequencies.

Tazobactam: Tazobactam was negative in microbial mutagenicity assays at concentrations up to 333 mcg/plate. Tazobactam was negative in the UDS test at concentrations up to 2000 mcg/mL. Tazobactam was negative in a mammalian point mutation (Chinese hamster ovary cell HPRT) assay at concentrations up to 5000 mcg/mL. In another mammalian point mutation (mouse lymphoma cells) assay, tazobactam was positive at concentrations ≥ 3000 mcg/mL. Tazobactam was negative in a cell (BALB/c-3T3) transformation assay at concentrations up to 900 mcg/mL. In an in vitro cytogenetics (Chinese hamster lung cells) assay, tazobactam was negative at concentrations up to 3000 mcg/mL. In vivo, tazobactam did not induce chromosomal aberrations in rats at IV doses up to 5000 mg/kg, which is 23 times the human dose based on body-surface area (mg/m^2).

BIBLIOGRAPHY

1. Fortner, C., Finley, R., Schimpff, S. Piperacillin sodium: Antibacterial spectrum, pharmacokinetics, clinical efficacy and adverse reactions. *Pharmacother* 1982; 2:287-299.
2. Holmes B., Richards D., Brogden R., Heel R. Piperacillin, A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use. *Drugs* 1984; 28(5):375-425.
3. Russo J., Thompson M., Russo M.E., et al. Piperacillin Distribution into Bile, Gallbladder Wall, Abdominal Skeletal Muscle and Adipose Tissue in Surgical Patients. *Antimicrob Agents Chemother* 1982; 22(3):488-492.
4. Morrison, J., Batra, V. Pharmacokinetics of Piperacillin Sodium in Man. *Drugs Exptl Clin Res* 1979; 5(2-3):105-110.
5. Tjandramaga, T., Mullie, A., Verbesselt, R., De Schepper, P., Verbist, L. Piperacillin: Human Pharmacokinetics After Intravenous and Intramuscular Administration. *Antimicrob Agents Chemother* 1978; 14(6):829-837.
6. Verbist, L. In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity. *Antimicrob Agents Chemother* 1978; 13(3):349-357.
7. Winston, D.J., Murphy, W., Young, L.S., Hewitt, W. Piperacillin therapy for serious bacterial Infections. *Am J Med* 1980; 69:255-261.
8. Hyodo, A., Hanehara, C., Miyake, Y., Ishida, N. YTR-830 Inhibitory Activity on Beta-Lactamases. Taiho Pharmaceutical Co., Ltd. 1984; Report y-30603. Data on file.

9. Higashitani, F., Hyodo, A., Ishida, N., Inoue, M., Mitsuhashi, S. Inhibition of Beta-Lactamases by tazobactam and in vitro antibacterial activity of tazobactam combined with piperacillin. *J Antimicrob Chemother* 1990; 25(4):567-574.
10. Diver, J.M., Thornber, D., Wise, R. Protection of Piperacillin and Ticarcillin from Beta-Lactamase Hydrolysis by Tazobactam (YTR 830) and Clavulanic Acid. *J Antimicrob Chemother* 1989; 24(1):89-92.
11. Jones, R.N., Pfaller, M.A., Fuchs, P.C., Aldridge, K., Allen, S.D., Gerlach, E.H. Piperacillin/Tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 *Bacteroides fragilis* group strains. *Diagn Microbiol Infect Dis* 1989; 12(6):489-494.
12. Wise, R., Gillett, A., Cadge, B., Durham, S., Baker, S. The influence of protein binding upon tissue fluid levels of 6 beta-lactam antibiotics. *J Infect Dis* 1980; 142:77-82.
13. Kuck, N.A., Petersen, P.J., Weiss, W.J., Testa, R.T. In Vitro and In Vivo Efficacy of YTR-830H and Piperacillin Combinations Versus Beta-Lactamase Producing Bacteria. *J Chemother* 1989; 1(3):155-161.
14. Stobberingh, E.E., In Vitro Effect of YTR (Tazobactam) on Plasmid and Chromosomally Mediated Beta-Lactamases. *Chemother* 1990; 36:209-214.
15. Neu, H.C., Niu, W., Chin, N. Tazobactam Prevention of Emergence of Resistance. *Diagn Microbiol Infect Dis* 1989; 12:477-480.
16. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved Standard January, 2000; M7-A5, Vol 20, No. 2, NCCLS, Wayne, PA.

17. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 6th ed., Approved Standard NCCLS Document January, 2000; M2-A8, Vol.23, No.1, NCCLS, Wayne, PA.
18. Cullmann, W., Stieglitz, M. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates. *Chemotherapy* 1990; 36(5):356-364.
19. De Schepper P., Tjandramaga T., Mullie A., et al. Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure. *J Antimicrob Chemother* 1982; 9 (Suppl B):49-57.
20. Roy, C., Tirado, M., Teruel, D., Reig, R., Rafols, M. Efficacy of tazobactam, a beta-lactamase inhibitor, in combination with piperacillin, against strains resistant to this penicillin. *Med Clin* 1989; 92(10):371-374.
21. A Double Blind, Placebo Controlled, Multiple Dose Safety, Tolerance and Pharmacokinetic Study of Piperacillin and Tazobactam After 30 Minute Infusion Every Four Hours to Healthy Adult Male Volunteers. (Study No.68-26). Data on file.
22. An Ascending, Multiple Dose, Safety, Tolerance and Pharmacokinetic Study of Piperacillin and Tazobactam After A Five-Minute Intravenous Injection Every Six Hours In Healthy Adult Male Volunteers. (Study No. 68-33). Data on file.
23. Bruckner O., Trautmann M., Martens F. Serum pharmacokinetics of piperacillin in cirrhosis patients. *Zeitschr Antimikrob Antineoplast Chemother* 1985; 3(2):79-83.
24. An Open Label, Non-Comparative, Safety, Efficacy, and Pharmacokinetic Study of Parenteral Piperacillin/Tazobactam (CL 298,741) Plus Tobramycin in the Treatment of Hospitalized Patients with Neutropenia and Bacterial Infection. (Study No. 68-27). Data on file.

25. The Pharmacokinetics and tissue Penetration of Tazobactam Administered Alone and With Piperacillin. (Study No. 68-528). Data on file.
26. Timmer, E. Piperacillin/tazobactam found to be a useful new antimicrobial. *Br J Clin Pract* 1989; 43(10):368.
27. Wise, R., Logan, M., Cooper, M., Andrews, J.M. Pharmacokinetics and Tissue Penetration of Tazobactam Administered Alone and with Piperacillin. *Antimicrob Agents Chemother* 1991; 35(16):1081-1084.
28. Gooding P.G., Clark, B.J., Sathe, S.S. Piperacillin: A Review of Clinical Experience. *J. Antimicrob Chemother* 1982; 9:Suppl.B, 93-99.
29. A Randomized, Open-Label, Comparative, Multicenter, Safety, Tolerance and Efficacy Study of Parenteral Piperacillin/Tazobactam (CL 298,741) Versus Clindamycin Plus Gentamicin in the Treatment of Hospitalized Patients with Intra-abdominal Infections. (Study No. 68-17). Data on file.
30. A Double-Blind, Randomized, Comparative, Multicenter, Safety, Tolerance and Efficacy Study of Piperacillin/Tazobactam (CL 298,741) Versus Ticarcillin/Clavulanate (TIMENTIN) for the Treatment of Hospitalized Patients With Skin and Skin Structure Infections. (Study No. 68-9). Data on file.
31. A Randomized, Open-Label, Comparative, Multicenter, Safety, Tolerance and Efficacy Study of Parenteral Piperacillin/Tazobactam Plus Tobramycin Sufate (NEBCIN) versus Imipenem/Cilastatin (PRIMAXIN) Plus Tobramycin Sulfate (NEBCIN) in the Treatment of Hospitalized Patients with Neutropenia and Bacterial Infection. (Study No. 68-19). Data on file.
32. A Randomized, Open-Label, Comparative, Multicenter, Safety, Tolerance and Efficacy Study of Parenteral Piperacillin/Tazobactam (CL 298,741) Versus Imipenem/Cilastatin

- in the Treatment of Hospitalized Patients with Intra-abdominal Infections. (Study No. 68-521). Data on file.
33. Summary of the Safety, Tolerance and Efficacy of Parenteral Piperacillin/Tazobactam in the Treatment of Hospitalized Patients with Intra-abdominal Infections (Study Nos. 68-505, 68-515, 68-521); Skin and Skin Structure Infections (Study No. 68-516); Complicated Urinary Tract Infections (Study No. 68-514); Lower Respiratory Tract Infections (Study No. 68-513); and Infections in Neutropenic Patients (Study No. 68-523). Data on file.
 34. Neu, H.C. Beta-lactamases, beta-lactamase inhibitors, and skin and skin-structure infections. *J Am Acad Dermatol* 1990; 22(5,Pt 1):896-904.
 35. National Committee for Clinical Laboratory Standards, Performance Standard for Antimicrobial Disk Susceptibility Tests - Sixth Edition. Approved Standard NCCLS Document M2-A 8, Vol. 23, No. 1, NCCLS, Wayne, PA, January, 2000.
 36. National Committee for Clinical Laboratory Standards, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition, Approved Standard NCCLS Document M7-A5, Vol. 20, No. 2, NCCLS, Wayne, PA, January, 2000.
 37. National Committee for Clinical Laboratory Standards, Methods for Antimicrobial Susceptibility Testing for Anaerobic Bacteria - Third Edition. Approved Standard NCCLS Document M11-A5, Vol. 17, No. 22, NCCLS, Villanova, PA, December, 2001.
 38. National Committee for Clinical Laboratory Standards, Performance Standard for Antimicrobial Susceptibility Testing; Fourth Informational Supplement, Approved Standard NCCLS Document M100-S4 (ISBN 1-56238-136-9), NCCLS, Villanova, PA, 1992.

39. Single-dose, open-label, parallel, pharmacokinetic study of piperacillin and tazobactam after intravenous infusion in normal subjects and subjects with liver cirrhosis. (Study No. 68-31). Data on file.
40. Yatsu JS, Kinzig M, Bansal S, Tonelli F, Sorgel F: Biliary concentrations of tazobactam and piperacillin in humans. Abs 18th Int Congr Chemother 1993:257 (Abs 805).
41. Tanimura H, Uchiyama K, Ishimoto K: Bile excretion of piperacillin in combination with tazobactam. Abs 18th Int Congr Chemother 1993:257 (Abs 806).
42. Reformulated Zosyn (EDTA Formulation) Y-Site Compatibility (Concurrent or Sequential Administration with Flushing Study with Aminoglycosides. RPT-58383. Data on file.
43. Compatibility of Reformulated Zosyn (EDTA Formulation) in admixture with Various Diluents. RPT-58381. Data on file.
44. Zosyn (Sterile Piperacillin Sodium and Tazobactam Sodium) EDTA Formulation's Admixture Study with Various Diluents After Storage for One Week Refrigeration. RPT-59077. Data on file.
45. Pharmaceutical Development Report: Zosyn EDTA Formulation for Injection Vials, 2.25 g, 3.375 g, 4.5 g and 40.5 g Lyophilized Powder. RPT-59067. Data on file.